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1.  Introduction  
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the 
‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by 
a majority of its members, consider that the information provided by the Member 
State on a new psychoactive substance merits the collection of further information, 
this information shall be collated and presented by Europol and the EMCDDA in the 
form of a Joint Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be 
submitted to the Council, the European Medicines Agency (EMA) and the 
Commission. 
At the end of September 2013, the EMCDDA and Europol examined the available 
information on a new psychoactive substance 3,4-methylenedioxypyrovalerone, 
commonly known by the abbreviation ‘MDPV’, through a joint assessment based 
upon the following criteria: 
1. the amount of the material seized; 
2. evidence of organised crime involvement; 
3. evidence of international trafficking; 
4. analogy with better-studied compounds; 
5. evidence of the potential for further (rapid) spread; and, 
6. evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information collected on MDPV satisfied 
criteria 1, 2, 3, 4 and 6. The two organisations therefore concluded that sufficient 
information had been accumulated to merit the production of a Joint Report on MDPV 
as stipulated by Article 5.1 of the Decision. 
2. Information collection process 
In compliance with the provisions of the Decision, on 7 October 2013 the EMCDDA 
and Europol launched a procedure for the collection of information on MDPV, in order 
to prepare the Joint Report. The information was collected mainly through the Reitox 
National Focal Points in the Member States, Turkey and Norway as well as the 
Europol National Units. In addition, the EMA collected information through the 
national competent authorities responsible for human and veterinary medicinal 
 
(1) OJ L 127, 20.5.2005, p. 32. 
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products in the Member States as well as in Norway and Iceland. The information 
collection process was largely concluded by 18 November 2013; additional 
information and clarifications from some countries were received up to four weeks 
after this date. 
Europol asked the Europol National Units to provide information on: 
• the level of production of MDPV in their country; 
• the level of distribution of MDPV in their country; 
• the level of trafficking of MDPV in their country, both for internal, transit or 
export purposes; 
• the number of seizures of MDPV in their country, the total amount of the 
seizures, country of origin, details on the physical forms (including photos); 
• the role of organised crime, or criminal groups, in the production, distribution 
and trafficking of MDPV in their country; and, 
• any known aspect of violence and/or money laundering relating to the 
production and trafficking of MDPV. 
Europol received responses from 15 Member States. 
According to Article 5.3 of the Decision, the EMA asked the national competent 
authorities responsible for human and veterinary medicinal products in the Member 
States as well as in Norway and Iceland to provide information on whether: 
• the new psychoactive substance MDPV has obtained a marketing 
authorisation; 
• the new psychoactive substance MDPV is the subject of an application for a 
marketing authorisation; and, 
• a marketing authorisation that had been granted in respect of the new 
psychoactive substance MDPV has been suspended. 
Twenty-five Member States (2), Norway and Iceland replied to the EMA’s request. 
The EMA also provided information as relevant to the central authorisation 
procedure. 
Furthermore, in anticipation of Article 7.3 of the Decision in relation to the 
manufacturing of medicinal products in the European Union, the EMA also requested 
whether the new psychoactive substance MDPV is used to manufacture a medicinal 
product: 
 
(2)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, 
Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom. 
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• which has been granted a marketing authorisation; 
• for which an application has been made for a marketing authorisation; and, 
• for which a marketing authorisation has been suspended by a competent 
authority. 
Twenty-four Member States (3), Norway and Iceland replied to the EMA’s request. 
The EMA also provided information as relevant to the central authorisation 
procedure. 
The EMCDDA collected data through: 
1. a structured questionnaire from the Reitox national focal points. The EMCDDA 
received replies from 28 Member States as well as Norway and Turkey; 
2. data previously provided to the EU Early warning system in EMCDDA-Europol 
Reporting forms, EWS Progress and Final Reports; 
3. a specific information request to the World Health Organization on whether or not 
MDPV is under assessment by the United Nations system (see section 3.5); and, 
4. a structured search of the scientific literature and of relevant Internet sites. 
Thus, information included in sections 3.2.1 and 3.3 of the Joint Report was provided 
by Europol, while the EMCDDA provided information included in sections 3.1, 3.2.2, 
3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included in sections 
3.8.3 (in part), 4.1, 4.2 and 4.3 was provided by the EMA. The conclusion of the Joint 
Report were prepared and agreed by the two organisations responsible — the 
EMCDDA and Europol. Further details of the seizures and collected samples 
(including images where available) reported to the EMCDDA are provided in Annex 
1. The details of deaths associated with MDPV that have been reported to the 
EMCDDA are provided in Annex 2. 
3.  Information required by Article 5.2 of the Decision 
 
The order and titles of subsections 3.1 to 3.8 and section 4 below are as they appear 
in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Decision; all sections are cross-
referenced with those set down in the Decision. 
 
(3) Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, 
Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom. 
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3.1 Chemical and physical description, including the names under which 
the new psychoactive substance is known — Article 5.2(a) of the 
Decision 
 
Chemical description and names 
 
MDPV is a synthetic derivative of the naturally occurring substance cathinone, one of 
the psychoactive principles in khat (Catha edulis Forsk). All monitored synthetic 
cathinone derivatives are either N-alkylated or the nitrogen atom is part of a 
pyrrolidine ring, which is the case with MDPV. Most of the cathinone derivatives are 
also ring-substituted and MDPV contains the 3,4-methylenedioxy substitution pattern 
on the phenyl ring which is observed in other illicit drugs such as MDMA (3,4-
methylenedioxymethamphetamine).  
 
Pyrrolidine derivatives, such as MDPV, can be regarded as a subset of cathinone 
derivatives sharing the same structural skeleton as pyrovalerone (Figure 1). Other 
examples in this group are 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP) and 4-
methyl-α-pyrrolidinobutyrophenone (MPBP).  
 
MDPV is the common name for 3,4-methylanedioxypyrovalerone. The systematic 
chemical name is: (RS)-1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one. 
 
Additional chemical synonyms reported are: 
 
1-(3,4-methylenedioxyphenyl)-2-pyrrolidinyl-pentan-1-one;  
1-(3,4-methylenedioxy-phenyl)-2-pyrrolidin-1-yl-pentan-1-one;  
1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one;  
1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one;  
1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;  
(RS)-[1-(3,4-metyleenidioksifenyyli)-2-(1-pyrrolidinyyli)-1-pentanoni)] (Finnish). 
 
Common names or codenames that have also been reported are: MDPK and 
metyleenidioksipyrovaleroni (Finnish). 
 
The following street names have also been reported: MDPK, Magic, Super coke, 
Peevee, New Ivory Wave, Kannibaldrogen, Apdamm, Aakkoset (meaning alphabet in 
Finnish), Bath salt, MP, MP4 and MP3. 
 
Finally, the following ‘legal high’ product names have been associated with MDPV: 
‘Mojo’, ‘Yellow Submarine’, ‘Ivory Wave’, ‘Vanilla sky’, ‘NRG-3’, ‘Flower magic’, ‘Gumi 
cucoriedka’, ‘Kamikadze’, ‘Xtacy’, ‘Ivory wave’, ‘Extreme star dust’, ‘Hurricane 
Charlie’, ‘Dogs bollix’, ‘Doves red’, ‘Doves ultra’, ‘Sextasy’, ‘Orange orbits’, ‘Stardust’, 
‘Blow’, ‘Recharge’, ‘Charge+’, ‘Lucky’, ‘Generation 2012’, ‘EL PADRINO’ (translation: 
the Godfather), ‘Coco Jumbo’, ‘Cherry Coco Jumbo’, ‘SUNRISE’, ‘TECHNO’, 
‘Greenway Speedway’, ‘DANA’, ‘OLGA’, ‘LENA’, ‘EVA’, ‘CLARA’, ‘MARKETA’ and 
‘JANA’. 
7 
 
Figure 1. Molecular structure, weight and monoisotopic mass of MDPV. The 
molecular structure for pyrovalerone is provided for comparison (* denotes the chiral 
centre). 
 
MDPV  pyrovalerone 
 
Molecular formula: C16H21NO3 
 
Molecular weight:  275.3429 
 
Monoisotopic mass: 275.152 
 
 
 
Chemical Abstract Service registry numbers (CAS RN) 
 
687603-66-3   free base 
24622-62-6   hydrochloride salt 
1388142-27-5  R-enantiomer base 
1388142-28-6  S-enantiomer base 
1246912-12-8  deuterated (D8) base 
1246820-09-6  deuterated (D8) hydrochloride salt 
 
The REACH registered substances database hosted by the European Chemicals 
Agency (ECHA) was searched using the CAS registry numbers listed above. The 
search returned no results. 
 
Physical description  
 
The free base form of MDPV has been described to be a brown or yellow-green 
amorphous powder. The hydrochloride salt form is described as a white-tan 
crystalline hygroscopic powder with a melting point of 238–239oC. 
 
* * 
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Reports from seizures and collected samples have noted the presence of MDPV in: 
powders, powder-filled capsules, tablets, blotters (small paper doses for 
sublingual/buccal administration), liquids, vegetable material, and, in residues on 
injecting equipment. 
 
A more detailed description of MDPV seizures and collected samples encountered 
can be found in subsections 3.2.1 and 3.2.2 below.  
3.2  Information on the frequency, circumstances and/or quantities in which 
a new psychoactive substance is encountered, and information on the 
means and methods of manufacture of the new psychoactive substance 
— Article 5.2(b) of the Decision 
3.2.1 Information provided to Europol 
Europol received replies from 15 Member States: Belgium, Bulgaria, Croatia, Cyprus, 
Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Luxembourg, Poland, 
Slovakia and Slovenia. Of these, four countries had no data relating to MDPV: 
Cyprus, Latvia, Luxembourg and Slovenia. The remaining 11 countries: Belgium, 
Bulgaria, Croatia, Estonia, Finland, Germany, Hungary, Italy, Lithuania, Poland and 
Slovakia reported the following information. 
The level of production, distribution and trafficking 
Belgium reported that in 2013 there were, so far eight cases in total, where MDPV 
was sent from China and entered Belgium en-route to third countries. The final 
destinations in these cases were: Italy (3 cases), the Netherlands (3) and the United 
Kingdom (2). The seized MDPV destined for Italy ranged from 18 grams to 510 g. On 
two occasions the substance was labelled as ‘ULTRAVIOLET AB’ (18 grams and 510 
grams) and as ‘LITHOPHONE’ (100 grams) on the remaining occasion. The MDPV 
ordered by consumers in the Netherlands was labelled as ‘SODIUM ALGINATE’, with 
the following quantities seized: 1516 grams, 1521 grams and 2022 grams. In one of 
the two cases when MDPV was destined for the United Kingdom market (which 
weighed 260 grams in each case), the seized substance was labelled as 
‘HETASTARCH’. 
Bulgaria reported that Customs have reported 12 seizures of MDPV made between 
July 2010 and March 2012. All seizures took place at Sofia Airport, when the 
substance was sent to Bulgaria (in the majority of cases) from: China, Spain, 
Portugal, the United Kingdom or the Netherlands. One case was reported which 
involved almost 5000 small packages of MDPV being sent to Poland via Hungary. In 
these 12 seizures 5267 grams and 300 tablets of MDPV were seized. In some cases 
MDPV powder was mixed with caffeine and lidocaine. MDPV tablets had a pink 
colour, elliptic shape and were packed in small packages (containing 2 tablets each) 
bearing label: ‘DOVES RED’. MDPV in powder form was identified in small packages 
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bearing different labels, for example, ‘IVORY WAVE’, ‘MOJO’, ‘FLOWER MAGIC 
POWDER’ and ‘LOAD’. 
In addition, the Bulgarian authorities reported that currently the Research Institute of 
Forensic Sciences and Criminology of the Ministry of the Interior has recorded 19 
cases related to MDPV seizures. In some of these cases MDPV was destined to 
smart shops located in nearby resorts at the Black Sea. 
Croatia provided information that MDPV was detected in 10 cases (14 grams in 
total). 
Estonia reported one seizure of MDPV (1.68 grams), made by Customs in incoming 
mail from the United Kingdom. In this case, MDPV was mixed with alpha-PVP and 
pentedrone.  
Finland reported that a few years ago, the number of seizures of MDPV was higher. 
Since the substance was classified as a controlled substance, the number of 
seizures declined. According to data provided by Finland, there were eight incidents 
where MDPV was seized in powder form (63.5 grams in total). There is also 
information that MDPV was identified in 11 blood samples (no further details were 
provided to Europol). 
The German contribution to Europol mentioned two significant investigations during 
which seizures of MDPV were recorded. 
The first investigation was conducted between September 2011 and March 2013. It 
was focused on distribution of new psychoactive substances sold via the Internet as 
so-called ‘legal high’ products. During house searches made in March 2013, 5524 
products containing new psychoactive substances (NPS) were seized. Moreover 
during further mail confiscation another 3999 NPS products were seized. Among 
these, the following products contained MDPV: 
10 packages (1 gram each) of the ‘bath salt’ named ‘Charlie Sheen’; 
11 packages (1 gram each) of the ‘bath salt’ named ‘Mojo’; 
20 capsules (0.5 grams each).  
Further analysis revealed that more than 4000 customers from Germany and foreign 
countries had used this now disrupted network. The NPS products were ordered by 
wholesalers in Belgium, the Netherlands, the Czech Republic, Portugal and Belize. 
The second investigation involved online vendors who were involved in supplying 
MDPV and methoxetamine. In the framework of this investigation, 30 kilograms of 
different NPS products were seized. Amongst others the following seizures of MDPV 
were identified: 
4 packages (1 gram each) of the ‘bath salt’ named ‘highway’; 
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6.29 grams of a white powder labelled as ‘4-FMP’; 
13.58 grams of a white powder labelled as ‘MDPV’; 
0.94 grams of a white powder labelled as ‘ECKO’, mixed with caffeine; 
a total of 90 grams of a white powder with different labelling: ‘MDPV’, 
‘methylone’, ‘4-FA’, with a purity of 73 %; 
a total of 2.568 grams of a white powder with different labelling: ‘MDMAI’, 
‘MPPP’, ‘Dimethocaine’, ‘Alpha PPP’, with a purity of 81 %; 
1.431 grams of a white and beige powder with different labelling: ‘Synthacain’, 
‘Charge+’, ‘Dimethocaine’, ‘R-MMC’, ‘Dichloropan’, without labelling; with a 
purity of 62 %; 
1 gram of a white powder labelled as ‘Alpha-PPP’; 
14 grams of a white powder labelled as ‘Alpha-PVP’; 
30 grams of a brown powder; 
61 packages of the so called ‘legal high’ product named ‘Brutal powder’, 
mixed with caffeine and lidocaine; 
10 grams of a white powder labelled as ‘Dichloropan’; 
28 grams of a white powder labelled as ‘Dimethocaine’; 
24 grams of green tablets, also containing caffeine; 
78 grams of green tablets ‘Benzo F’; also containing caffeine; 
6 grams of a white powder labelled as ‘Synthacain’; 
20 packages of the ‘bath salt’ named ‘Tony Montana’ (4), also containing 
caffeine and lidocaine.  
Data provided by Germany concerning MDPV seizures were recorded from February 
2011 and November 2013. There has been huge number of seizures where MDPV 
was detected. Bearing in mind the number of seizures and level of distribution it can 
be concluded that market for the MDPV has been rising during the last years. 
German authorities assume that the number of unreported cases, in relation to 
MDPV is high. In the majority of cases MDPV was identified in so called ‘legal high’ 
products, with different labelling: ‘Mojo’, ‘Mitseez’, ‘Buzz Powder’, ‘Sweed’, ‘Ivory 
Wave’, ‘J White Powder Cleaner’, ‘wakup’, ‘Yellow Submarine’, ‘XXX’, ‘Buty’, 
‘Lionheart’, ‘Rush Hour’, ‘Lets play crack inside’, ‘Charlie Sheen’, ‘All Day, All Night – 
What the fuck’, ‘Highway’, ‘ECKO’, ‘Brutal Powder’, ‘Sextacy’, ‘Insomnia’ and ‘Ultra 
Charge’.  
In most of these cases, MDPV was identified as main active ingredient mixed with 
other new psychoactive substances and/or adulterants like: 4-MEC, flephedrone, 
butylone, MDPBP, TFMPP, 3-FMC, MXE, 2C-E, para-fluoramphetamine, AM-2201, 
pentedrone and/or lidocaine, caffeine, starch, taurine, mannitol and benzocaine. 
The seizures of MDPV ranged from 0.02 grams (March 2012) to 1 kilogram (January 
2013 – 2 x 500 grams). 
 
(4)  ‘Tony Montana’ is the name of Al Pacino’s character in the 1983 film ‘Scarface’, directed by 
Brian de Palma, which tells the story of a Cuban refugee who becomes a drug kingpin in the 
cocaine trade in Miami, USA. 
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In Hungary, the increase in availability, use and distribution of MDPV led the Ministry 
of Justice to propose an amendment to the Act on Drugs which then placed MDPV 
as a Class A drug. The Hungarian Europol Liaison Officer reported that MDPV has 
been seized in tablet and powder form in 2009 and 2010 respectively. 
Seizures of MDPV tablets have risen from 551 tablets in 2009 (6 cases) to 8522 
tablets in 2012 (9 cases). Seizures of powder have evolved from 133 grams in 2010 
to 9579 grams in 2010 and to 5730 grams in 2012. In 2013 the seizures of MDPV 
(both tablets and powder form) have been noted to have dropped significantly.  
Italy reported a limited number of seizures of MDPV. There were three seizures of 
MDPV (in total, 307.6 grams) made in the provinces of Roma, Milano and Taranto 
(September – October 2013). The involvement of Italian citizens has been reported in 
these cases. 
Lithuania reported four seizures of MDPV made in 2012, totalling 1.326 grams. 
In Poland, MDPV was seized as powder in quantities ranging from 0.11 grams to 525 
grams. This is the largest seizure, which was made in April 2013, when the 
substance was sent from China (ordered via: www.sensearomatic.com) to Poland by 
shipping company FedEx. 
Slovakia reported 24 cases where MDPV was seized as a powder (different colours). 
In a significant majority of cases, the substance was seized in small packages 
labelled with different names: ‘Long Play’ (8 cases); ‘Beep beep’ (8); ‘Speed way’ (1); 
‘Popeyes Sniff’ (1) and ‘LP’ (1). In almost all cases, MDPV was identified in a mixture 
with other new psychoactive substances such as: 2-DPMP (5) and buphedrone 
(majority), MABP, bk-MDMA and ethcathinone. Seizures of MDPV weighed between 
0.218 grams and 53.315 grams. 
The Slovakian Financial Administration reported a case focused on a smart shop 
(Euphoria Shop Ltd.), which distributed goods called ‘Aromatic herbs and imitations 
of spa salts’. The Forensic Institute revealed that the products contained MDPV. The 
distribution of goods took place via branches in six cities in Slovakia. In June 2012, 
during searches made in these branches and in the house of a suspect, a total 
amount of 19,562 packages containing MDPV were seized. In addition, 5 plastic 
bags with crystalline white powder were seized (20 grams, 80 grams, 300 grams, 800 
grams, 1 kilogram) and EUR 6191 in cash.  
In addition, Slovakia reported a seizure of 10 kilograms of MDPV powder seized by 
Customs officers of Airport Financial Administration (no other details provided). 
According to Slovakian authorities, imports are ordered via the Internet and then 
delivered from China to Slovakia by mail order (DHL, TNT, FedEx, etc.). 
 
(5) 2-(Diphenylmethyl)piperidine 
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No reports were received that indicated licit or illicit production of MDPV in any of 
these countries.  
3.2.2  Information provided to the EMCDDA 
 
According to reports to the EMCDDA, MDPV has been present on the EU drugs 
market since 2008 and subsequently a large volume of data has been collected 
during this period, of which a summary is presented below. 
 
Twenty-seven Member States (all Member States with the exception of Luxembourg) 
and Norway and Turkey reported detections of MDPV (6). 
Seizures  
Twenty-seven Member States (all Member States with the exception of 
Luxembourg), Norway and Turkey have reported seizures (7) of MDPV to the 
EMCDDA. In excess of 5500 seizures have been reported with two countries 
reporting more than 1000 seizures each: the United Kingdom (1704) and Finland 
(1340). A further four countries reported more than 100 seizures: Hungary (599), 
Poland (401), Ireland (242) and Spain (176).  
MDPV has typically been seized in powder form (reported by all countries where 
MDPV was detected). Some countries also reported seizures of tablets or powder-
filled capsules (Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, 
Norway, Poland, Portugal, Romania, Spain, Sweden, and the United Kingdom). Six 
countries (Denmark, Finland, France, Latvia, Sweden, and the United Kingdom) have 
seized liquids containing MDPV. Finland and Poland each reported a single seizure 
of paper doses (also known as a ‘blotters’), i.e. small pieces of paper impregnated 
with MDPV for sublingual/buccal administration. The Polish blotters (4 in total) had an 
image of Bugs Bunny on them and also contained 2-DPMP, ethylphenidate and the 
nootropic substance piracetam. Hungary also reported two cases where MDPV was 
present as ‘powder on herb’ and Poland reported a seizure of a ‘legal high’ product 
labelled as ‘Greenway Speedway’, which contained vegetable material with MDPV 
present. Indeed, MDPV has often been found as an ingredient in so-called ‘legal 
high’ products, often in combination with other substances. Several countries have 
described these as ‘bath salts’, a term frequently used to describe ‘legal high’ 
 
(6) ‘Detections’ is an all-encompassing term and may include seizures and/or collected and/or 
biological samples. Seizure means a substance available (seized) through law enforcement 
activities (police, customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, etc.) and/or 
specimens (tissues, hair, etc.)  
(7)  Many ‘seizures’ relate to individual case-level data, however, some data provided to the 
EMCDDA are aggregated at the country level. Some of the data from the United Kingdom are 
reported as ‘records’, where several records may come from the same case. Data is drawn 
from the Joint Report questionnaires and data provided in the bi-annual data gathering (EWS 
progress and final reports) and from individual Reporting forms submitted on an ad hoc basis. 
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products. Several of these products carry names that are associated with or similar to 
street-names used for cocaine, amphetamine or ‘ecstasy’ (MDMA). Other substances 
found along with MDPV in the same preparation include a wide range of new 
psychoactive substances (predominantly cathinones, but also phenethylamines, 
piperazines, synthetic cannabinoid receptor agonists and a range of other 
substances), adulterants such as benzocaine, lidocaine and caffeine and in a smaller 
number of cases, with substances that are internationally controlled or controlled at 
EU-level.  
Where information has been provided, quantities of powder for single seizures 
ranged from 0.02 grams (Germany and Poland) to 5 kilograms (Czech Republic). 
Hungary reported a seizure of 300 yellow tablets bearing a heart logo and a separate 
seizure of two white tablets bearing markings resembling the Louis Vuitton ‘LV’ logo 
(8). Norway reported a seizure of 98 purple tablets bearing a spaceship/rocket logo. 
These tablet findings may suggest that MDPV is being sold as ’ecstasy’. There were 
also unmarked tablets reported in a variety of colours including white, grey, pink, 
reddish and green, although many of these were associated with ‘legal high’ 
products. A selection of images is provided in Annex 1. 
More than 4500 individual MDPV powder cases have been reported, amounting to an 
excess of 200 kilograms of seized MDPV. The vast majority of these are small cases, 
however, 45 of these cases (reported by the Czech Republic, Finland, France, 
Hungary, Latvia, the Netherlands, Spain and Sweden) were in excess of 500 grams 
accounting for more than approximately one third of the total weight of powder 
seized. In 2011, for example, Customs authorities in Hungary made 7 separate 
seizures of MDPV powder amounting to approximately 14.5 kilograms. Belgium, the 
Czech Republic, Germany and Lithuania provided information that MDPV seized by 
customs authorities had been sent from China. No other non-EU countries were 
identified in the reports, although two Member States reported the interception of 
packages sent from another Member State. Several countries reported MDPV in 
powders contained in ‘legal high’ products with names such as Charlie Sheen, 
synthacaine or speedway pro (a full list of names is provided in Section 3.1 above).  
There were over 500 cases involving MDPV tablets or capsules, containing 
approximately 30,000 tablets in total. Several countries reported tablets containing 
MDPV in branded ‘legal high’ products with names such as ‘Yellow submarine’, 
‘Doves red’ and ‘Mind candy’ (a full list of names is provided in Section 3.1 above).  
Biological samples 
Eleven countries reported detections of MDPV in biological samples, including:  
 
(8) It is common to find markings on tablets sold as ‘ecstasy’ including those of popular cultural 
and iconic brands often having an association with quality. Louis Vuitton is a French fashion 
label. 
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• a total of 99 deaths: Finland (40 deaths), United Kingdom (32), Sweden (21), 
Poland (3), Austria, France and Norway (1) – see section 3.4.1 and Annex 2 
for further details 
• 107 analytically confirmed non-fatal intoxications: Sweden (99 cases), France 
(3), Italy (3) and Belgium (2) 
• detections related to cases of suspicion of driving under the influence of drugs 
(Finland (514 in the period 2009-2013), Poland (1)); driving under the 
influence of drugs and other crimes (Norway (9), United Kingdom (1)); drug 
testing (Poland (1)); as well as unspecified detections in biological samples 
(Sweden (842), Hungary (387), United Kingdom (6) and Norway (6)) 
Collected samples  
In addition to the detections of MDPV in seizures and biological samples, ten 
Member States (Austria, Cyprus, Denmark, France, Ireland, Italy, the Netherlands, 
Poland, Slovakia and the United Kingdom) also reported collected samples. 
In Austria, 32 samples of powder were collected and analysed as part of the ‘pill’-
testing project run by ‘ChEckiT!’ between 2010 and 2013. The samples were sold as 
mephedrone, cocaine, MDPV and speed. In two cases, amphetamine and caffeine or 
bk-MBDB (9) were also detected.  
France reported nine samples of powder collected from different venues. Where 
quantitative information is available, the weight ranged from 0.1 to 0.5 grams. In two 
of the samples alpha-PVP and pentedrone were also detected; in the other sample 
alpha-PVP and caffeine were detected. In one of the cases the sample was sold as 
cocaine. 
In Ireland, MDPV was identified in products collected from headshops branded 
‘Hurricane Charlie’, ‘Dogs Bollix’, ‘Doves Red’, ‘Doves Ultra’, ‘Ivory Wave’, ‘Sextasy’, 
‘Orange Orbits’ and ‘Stardust’. 
In the Netherlands, the Drugs Information and Monitoring System (DIMS) detected 
MDPV in 27 samples (11 in 2010, 9 in 2012 and 7 in 2013). Where information is 
provided, the samples were sold at consumer level as sold as MDPV (1 sample), 
cocaine (3), synthetic cocaine (2), ‘moji’ (1), 6-APB (10) (2), 5-APB (11) (1) and 
‘meferon’ (2). 
Poland reported 887 cases of branded products containing up to 500mg of MDPV 
mostly in powder form, as well as in tablets and capsules. Other substances detected 
in these samples are other synthetic cathinones (naphyrone, methedrone, 
 
(9)  2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one, also known as butylone. 
(10) 6-(aminopropyl)benzofuran. 
(11)  5-(aminopropyl)benzofuran. 
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buphedrone, pentedrone methylone, 4-MEC, FMC, MDPBP, butylone, BMDP), 
phenethylamines (pFPP, fluoroamphetamine, 2C-E), synthetic cannabinoids (RCS-4, 
JWH-122, JWH-081), TFMPP, 5-HTP, creatine, lidocaine, and caffeine.  
Slovakia reported a total of 304 collected samples; some of them were offered 
through online shops (i.e. www.euphoriashop.sk, www.hypnotic.sk) under a variety of 
names including ‘Beep Beep’, ‘Long Play’, ‘Popeyes Sniff’, ‘Speed Way’, etc. Other 
substances often detected in the samples include the synthetic cathinones 
buphedrone, N-ethylcathinone and methylone; 2-DPMP and piracetam. 
A small number of collected samples were reported by Cyprus, Denmark, Italy and 
the United Kingdom. In 2010, Cyprus reported MDPV in two samples of a product of 
500 mg labelled ‘Ivory wave’. Denmark reported three samples of powder in 2013. 
Italy reported a sample of 0.5 grams of white powder purchased from the Internet 
and branded ‘Ivory wave’. On the label at the back of the package, ingredients listed 
were ‘water softening agents, Epsom salts, sodium bicarbonate, sodium chloride, 
amino acid blends, and naturally occurring trace elements and minerals’. No other 
substances in addition to MDPV were detected. The United Kingdom reported a 
sample of 33 grams of MDPV powder purchased from an Internet retailer 
(http://www.chembay.co.uk) in December 2008.  
Further details of these collected samples, including information on the product 
labels, are provided in Annex 1. 
3.3 Information on the involvement of organised crime in the manufacture 
or trafficking of the new psychoactive substance — Article 5.2(c) of the 
Decision 
According to German authorities there are no links to suggest the involvement of 
organised crime groups in the production, trafficking and/or distribution of MDPV. It 
should be borne in mind that easy access to substances in and outside of the 
European Union (also in big amounts) via Internet shops indicates at least a certain 
level of organisation.  
In addition, the interest and presence of organised crime groups in the phenomenon 
of new psychoactive substances can be easily concluded from enormous attainable 
financial profits they can obtain from this type of criminal activities.  
Money laundering aspects 
No information was received on money laundering in connection with the production 
and/or trafficking of MDPV. 
Violence in connection with production, wholesale and distribution 
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No information was received on incidents of violence in connection with the 
production, wholesale and/or trafficking of MDPV. 
3.4 A first indication of the risks associated with the new psychoactive 
substance, including the health and social risks, and of the 
characteristics of users — Article 5.2(d) of the Decision   
3.4.1 First indication of health risks 
Up to 107 non-fatal intoxications and 99 deaths, analytically confirmed to be 
associated with MDPV were reported by Austria, Belgium, Finland, France, Italy, 
Poland, Sweden, the United Kingdom and Norway. In addition, Germany, Greece, 
Hungary, Ireland and Slokavia reported further cases which have not been described 
below due to their non-confirmed status. 
Non-fatal intoxications  
Belgium reported two analytically confirmed linked non-fatal intoxications in which the 
patients presented were stimulated, hypertensive and tachycardic. Traces of cocaine 
and amphetamines were also detected in urine samples (not quantified). They both 
reported visual and auditory hallucinations and severe psychosis, paranoia and were 
aggressive. They were treated with antipsychotics and their status returned to normal 
after 3-4 days. 
France reported three analytically confirmed non-fatal intoxication cases. In one 
case, a man was brought in to the emergency department by the police. In this case, 
delirium syndrome was reported, including hallucinations as well as rhabdomyolysis, 
tachycardia, hypotension, agitation, logorrhea and acute renal failure. The MDPV 
metabolite, pyrovalerone and cannabis were also detected in this case. In the second 
case, which was a ‘forced hospitalisation’, paranoid psychosis and aggression were 
noted. The symptoms reported were tachycardia, mydriasis, hypertension, agitation, 
profuse sweating, trembling, scarification and rhabdomyolysis. In this case, the route 
of administration was nasal and oral and the MDPV had been bought on the Internet. 
Methylone (4400 ng/ml) was also detected in this case. In the last case, where the 
detection of MDPV was in a sample of hair, the patient had also bought MDPV via 
the Internet and the route of administration was nasal. Symptoms reported were 
mydriasis and paranoid psychosis. Cannabis and alcohol were also detected in this 
case. 
Italy reported three analytically confirmed non-fatal intoxications. The first was from 
August 2011 when a 20 year old male was admitted to hospital very agitated with 
tachycardia (HR (12) 115 bpm). He reported having consumed cannabis, alcohol and 
three white capsules. MDPV was found in urine (14 mg/L) and butylone was also 
present (concentration not provided). The patient was treated with benzodiazepines 
 
(12)  Heart rate 
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and discharged two days later. The second case was from October 2012 and 
involved a 38 years old male who presented at the emergency department with 
agitation, mild tachycardia (HR 105 bpm), distress and psychotic symptoms. He also 
reported visual and auditory hallucinations. He reported to have taken ecstasy and 
synthetic drugs generally named as ‘mefre, crystal and energy’ by nasal insufflation. 
MDPV was detected in blood (12 mg/L) and urine (17 mg/L). Urine screening of 
ketamine, atropine, scopolamine, levamisole, mephedrone, butylone, 4-MEC, 
methoxetamine, APB (13) (isomers), 4-FA (14), and MDAI (15), resulted negative. The 
final case also occurred in October 2012 and involved a 27 years old male who 
presented at the emergency department. His father had found him in a state of 
agitation, confusion and anxiety. The patient reported having taken MDPV by 
intravenous injection for the last 3-4 days together with benzodiazepines to 
counteract the excitatory effect of MDPV. The MDPV had been purchased from the 
Internet as a ‘bath salt’. Analysis of the patient’s urine revealed MDPV (55 µg/L), 
alprazolam (113.79 µg/L) and hydroxyalprazolam (103.59 µg/L). Three days after 
admission, the patient returned to the hospital for a second urine analyses, as 
requested by sanitary authorities. The patient reported continuing his use of MDPV 
and this was confirmed by the detection of MDPV in urine at a concentration of 35 
µg/L. The analyses also found chlordiazepoxide (13.03 µg/L), nordiazepam (61.55 
µg/L), oxazepam (114.99 µg/L), diazepam (1.26 µg/L), temazepam (169.90 µg/L), 
alprazolam (10.43 µg/L) and alpha-hydroxyalprazolam (13.45 µg/L). 
Sweden reported 459 non-fatal intoxications between 2007 and 2013 as follows: 
2007 (1 case), 2008 (4), 2009 (15), 2010 (47), 2011 (32), 2012 (194) and 2013 (166). 
Of these, between 86 and 99 cases are known to be analytically confirmed (16). Two 
literature sources which describe a total of 99 non-fatal intoxications have been used 
for the purposes of describing the health risks. In the first report (Lindeman, et al., 
2013), cases of stimulant toxicity were studied from one hospital in Sweden covering 
April-May for three consecutive years (2010 to May 2012). In April-May 2012 the 
number of patients with stimulant toxicity was 45 and 17 of these cases were 
examined toxicologically. Thirteen of these tested positive for MDPV and 12 of these 
were classified as chronic drug users with >60% noted to be HCV (Hepatitis C virus) 
positive. The second study (Bäckberg et al., 2013) focussed on the results of the 
STRIDA project which monitors trends in acute poisonings with novel recreational 
drugs in Sweden. The study summarises the results for the first 9 months in 2012 
when MDPV was detected in 86 out of 321 samples. In 17 cases the symptoms were 
severe (Poisoning Severity Score - PSS 3 (Persson et al, 1998)) and consisted of 
extreme agitation, psychosis, hyperthermia, tachycardia, hypertension, myocardial 
infarction, rhabdomyolysis and renal failure. A few patients needed therapy with 
sedatives for several days due to prolonged symptoms. It was noted by the authors 
 
(13) (Aminopropyl)benzofuran 
(14) 4-Fluoroamphetamine 
(15) 3,4-Methylenedioxyaminoindane 
(16)  There is a potential that there may be an overlap of some cases reported by Lindeman et al., 
2013 and the cases reported by Bäckberg et al., 2013 
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that among people that come to medical attention, the incidence of severe 
poisonings (PSS 3) was highest for MDPV. 
Deaths 
There were 99 deaths associated with MDPV that were analytically confirmed. These 
were reported by Austria (1), Finland (40), France (1), Poland (3), Sweden (21) the 
United Kingdom (32) and Norway (1) (17). 
Austria 
Austria reported one death which occurred in January 2012. The case involved a 
‘young man’ who died from butylone (bk-MBDB) overdose in combination with 
MDPV, methylone and 4-MEC. No further details were provided. 
Finland 
Finland reported 40 deaths which occurred between September 2009 and August 
2013. The cases were all analytically confirmed and where the concentration of 
MDPV was reported (20 cases) it ranged from 20-4800 mg/mL in blood; in all but one 
case, up to seven other substances were detected. In fourteen cases, five or more 
substances were detected in addition to MDPV. The most frequently encountered 
other substances detected were diazepam (22 cases), amphetamine (14), 
buprenorphine (14), temazepam (9), alprazolam (8), ethanol (7), morphine (3) and 
pregabalin (3). Causes of death reported were accidental poisoning (22 cases), 
suicidal poisoning (4), suicide resulting from crushing injuries (2), suicide by hanging 
(2), suicide by carbon monoxide poisoning (1), unspecified intoxication (1), 
unspecified death and cirrhosis of liver (1), accidental injury to thoracic aorta (1), 
accidental death due to multiple rib fractures (1), infective myocarditis disease (1) 
and homicide (1). The cause of death was not yet registered in three cases. 
France 
France reported one death that occurred in October 2012. The cause of death was 
drowning. MDPV was present at a concentration of 106 µg/L (blood) and 760 µg/L 
(urine). Other drugs detected were PVP (18) (blood 40 µg/L; urine 295 µg/L), 
pentedrone (blood 33 µg/L; urine 110 µg/L), hydroxyzine (blood 194 µg/L), 
nordiazepam (blood 47 µg/L), oxazepam (blood 8 µg/L), cannabinoic acid (blood 15.7 
µg/L) and ethanol (blood 0.3 g/L). No further details were provided. 
Poland 
 
(17) Hungary reported two indirect deaths which occurred in November 2011. No further details 
were provided and it is not known if these cases are analytically confirmed. 
(18) Pyrrolidinovalerophenone  
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Poland reported three deaths associated with MDPV. The first death was in 
September 2010 and the reported cause of death was ‘metabolic dysfunction’ caused 
by MDPV. The concentration of MDPV determined in blood was 430 ng/mL and 
ephedrine was also detected at a concentration of 324 ng/mL. No further details were 
available. The second and third cases were reported from 2011. One of the cases 
involved a road traffic collision where one driver suffered severe injuries, resulting in 
his death. During the police investigation, packages of white powders, called ‘Ivory 
Speed’ and ‘Exclusive Dust’ were found (Adamowicz et al., 2013). MDPV was 
detected in blood at a concentration of 38 ng/mL and buphedrone was also detected 
at a concentration of 127 ng/mL. The third case involved a man with a history of drug 
addiction who was found unresponsive after a night of partying. A witness reported 
that he had taken a product called ‘Speedway’ while at the party. The post mortem 
examination showed emaciation, external hydrocephalus and atherosclerosis. The 
man also suffered from human immunodeficiency virus (HIV) infection (Adamowicz et 
al., 2013). MDPV was detected in blood at a concentration of 17 ng/mL and in 
addition clonazepam (1.2 ng/mL) and 7-aminoclonazepam (96 ng/mL) were also 
detected. 
Sweden 
Sweden reported twenty-one deaths: 3 in 2010, 3 in 2011, 9 in 2012 and 6 in 2013. 
Brief comments were reported as follows: in 2010 the deaths were intoxications 
involving several substances (not further described); in 2011 none of the three 
deaths related only to MDPV; in 2012 there were several accidents, death by 
hanging and intoxications with several drugs (not further described); and in 2013 
there was one car accident and intoxications with several drugs (not further 
described). 
United Kingdom 
The United Kingdom reported 32 deaths that occurred between January 2010 and an 
unspecified date in 2013 (12 in 2010, 8 in 2011, 12 in 2012 and 1 in 2013). 
Where reported, the causes of death were noted to be hanging (7 cases), cardiac-
related causes (19) (5), drug toxicity (4), drowning (2), carbon monoxide poisoning (2), 
asphyxia (1), multiple injuries (suicide) (2), hypovolemic shock due to laceration of 
left forearm associated with partial transection of cephalic vein (1). In the remaining 
cases the cause was either unascertained or not specified. In the cases of drug 
toxicity, MDPV was normally present with other drugs. Where reported, the most 
common other substances present were mephedrone (9 cases), 4-
fluoromethcathinone (7), cocaine (4), amphetamine (4) and MDMA (3), although a 
range of other controlled drugs and medicines were also detected. MDPV was not 
 
(19) Specifically: heart attack (1 case), cardiac arrest (1), cardiac failure (1), coronary artery disease 
(1) and ischemic heart disease (1). 
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the sole cause noted in any of the cases and was specifically implicated as a 
contributory factor in nine of the cases.  
Norway 
Norway reported one death in 2012 in which MDPV was detected during the 
toxicological examination of blood. The cause of death in this case was not reported 
and no further information was provided.  
Pharmacology and mode of action 
Work by Baumann et al., (2013a) provides a systematic evaluation of the 
pharmacology and mode of action of MDPV using in vitro and in vivo studies in 
rodents (20).  In vitro data shows that MDPV acts as a potent catecholamine-selective 
(dopamine and noradrenaline) transporter blocker (Table 1); sharing some 
similarities with the structurally related compound pyrovalerone. Compared to 
cocaine, MDPV is 50-fold more potent at DAT (dopamine transporter), 10-fold more 
potent at NET (norepinephrine transporter), and 10-fold less potent at SERT 
(serotonin transporter) (Baumann et al., 2013a). In addition the data also showed that 
MDPV does not act as a transporter substrate. Consistent with the in vitro data, in 
vivo microdialysis studies in rats found that MPDV increased extracellular 
concentrations of dopamine in the nucleus accumbens and was 10-fold more potent 
than cocaine; while in vivo locomotor activity testing (stereotypy and forward 
locomotion) and assessment of cardiovascular parameters (heart rate and blood 
pressure) found that MPDV is at least 10-fold more potent than cocaine in inducing 
locomotor activation, tachycardia and hypertension. The authors concluded that the 
‘potent blockade of dopamine uptake caused by MDPV predicts that the drug has a 
high risk for abuse, whereas the potent blockade of norepinephrine uptake portends 
dangerous cardiovascular stimulation’ (Baumann et al., 2013a). 
Simmler et al., (2012) using a human in vitro model assessed the blood-brain 
permeability of MDPV. They reported that MDPV exhibited particularly high blood-
brain barrier permeability as compared to other synthetic cathinones (with the 
exception of mephedrone) as well as reference compounds such as MDMA and 
amphetamine. In addition they reported that the data for MDPV was consistent with 
active transport across the blood-brain barrier. The authors concluded that the 
potency of MDPV at the DAT and NET and high blood–brain barrier permeability 
could ‘result in high sympathomimetic toxicity and risk of addiction in humans’. 
No studies were identified that have examined the pharmacology and mode of action 
of MDPV in humans. 
Meyer et al., (2010) and Strano-Rossi et al., (2010) provide data on the possible 
metabolites and metabolic pathways for MDPV in vitro using rat and/or human urine 
and human liver microsomes. 
 
(20) See also: Gregg and Rawls (2013); Huang et al., (2012);  
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Table 1. Transporter-mediated inhibition of uptake and stimulation of release in 
rat brain synaptosomes. Values are given as nM ± S.E.M. for N=3–4 experiments 
per drug. Emax% refers to percentage of maximal release response. Key: “—” indicate 
that compounds failed to elicit >30% of the maximal response and therefore 
compounds are considered inactive in the release assay. Modified from Baumann et 
al., (2013a,b). 
Compound DAT uptake 
IC50  
(nM ± 
S.E.M.) 
NET uptake 
IC50 
(nM ± 
S.E.M.) 
SERT 
uptake 
IC50  
(nM ± 
S.E.M.) 
DAT release 
EC50 (nM ± 
S.E.M.) 
[Emax %] 
NET release 
EC50 (nM ± 
S.E.M.) 
[Emax %] 
SERT release 
EC50 (nM ± 
S.E.M.) 
[Emax %] 
MDPV 4.1 ± 0.5 26 ± 8 3349 ± 305 
— — — 
Cocaine 211 ± 19 292 ± 34 313 ± 17 
— — — 
Mephedrone 762 ± 79 487 ± 66 422 ± 26 51 ± 5 
[102 ± 2] 
58 ± 11 
[99 ± 4] 
122 ± 10 
[101 ± 1] 
Methylone 1232 ± 133 1031 ± 162 1017 ± 59 117 ± 12 
[96 ± 1] 
140 ± 17 
[94 ± 2] 
234 ± 35 
[98 ± 2] 
MDMA 1009 ± 39 450 ± 30 125 ± 11 42 ± 2 
[100 ± 4] 
53 ± 7 
[95 ± 2] 
39 ± 5 
[103 ± 4] 
Amphetamine 93 ± 17 67 ± 16 3418 ± 314 5.8 ± 0.4 
[102 ± 1] 
6.6 ± 0.7 
[92 ± 1] 
698 ± 71 
[97 ± 2] 
Toxicology 
See ‘Pharmacology and mode of action’ (above) for an overview of some of the in 
vitro and in vivo animal data that is relevant to the toxicity of MDPV in humans. 
Simmler et al., (2013) examined the cytotoxicity of MDPV in vitro using a cell 
membrane integrity assay which measures the release of adenylate kinase from 
damaged cells. MDPV did not show apparent cytotoxicity at concentrations of 10 and 
100 µM after 4 h of incubation at 37°C. No studies were identified that have 
examined the toxicity of MDPV in humans. 
The clinical features of acute toxicity associated with MDPV use as reported by the 
Member States are provided in section 3.4.1 ‘Non-fatal intoxications’ and ‘Deaths’ as 
well as in Annex 2. These include a number of analytically confirmed cases. Case 
reports/series of intoxications where MDPV was analytical confirmed report similar 
findings (Spiller et al., 2011). 
Methods for the toxicological screening of MDPV in urine have been reported by 
Strano-Rossi et al., (2010) and in blood by Marinetti and Antonides (2013). 
Dependence and abuse potential 
A review by Gregg and Rawls (2013) provides an overview of the in vivo animal 
behavioural pharmacology studies relevant to the possible abuse potential of MPDV 
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in humans (21). They note that in rats the administration of MDPV both lowered 
intracranial self-stimulation thresholds and led to self-administration across multiple 
doses; while in a progressive-ratio model of reinforcement, higher doses of MDPV 
produced the highest breakpoints (Aarde et al., 2013; Watterson et al., 2012). In 
addition, dose-substitution studies suggested that MDPV possessed greater potency 
and efficacy than methamphetamine; with escalation studies showing that MDPV 
increases drug intake at similar doses to those observed with methamphetamine 
(Watterson et al., 2012). Finally they note that studies in mice undertaken by 
Fantegrossi et al., (2013) found that MDPV discriminates from saline and fully 
substitutes for MDMA and methamphetamine.  
The findings reviewed by Gregg and Rawls (2013) are supported by the work of 
Baumann et al., (2013) which are discussed in the section on ‘Pharmacology and 
mode of action (above). They note that based on the ‘potent and efficacious actions 
of MDPV on extracellular dopamine and motor activity’ shown in their study suggests 
that MDPV has a high potential for abuse. In addition, they suggest that given that 
MDPV has weak effect on SERT this may further enhance the reinforcing effects of 
the drug given that studies have shown that elevations in synaptic serotonin can 
dampen the stimulant effects mediated by dopamine (Baumann et al., 2011; Wee et 
al., 2005). No studies were identified that have examined the dependence and abuse 
potential of MDPV in humans. 
3.4.2 Characteristics of users 
The section below includes a discussion of the characteristics of users which 
includes information from self-reported use from Internet drug discussion forums and 
related websites (hereafter ‘user websites’). As such it is important to note that it is 
not possible to confirm the specific substance(s) used, nor the purity, dose, etc. 
Analysis of products containing new psychoactive substances that are sold on the 
drug market have shown that the composition can differ between that claimed by the 
retailer, as well as differ over different geographical areas and time. Similar caveats 
apply to these types of information that have been provided in case reports/series 
unless biological and collected samples were taken and subjected to toxicological 
and forensic analysis. In addition, the information provided by patients in case 
reports/series as well as that provided on user websites should be regarded as 
illustrative only and not taken as representative of users of MDPV in general. Finally, 
information from seizures, collected samples and user websites suggest that MDPV 
has been commonly sold as a ‘legal’ replacement for cocaine, amphetamine or 
‘ecstasy’ (MDMA). There is also information to suggest that MDPV has been sold 
directly on the illicit drug market as cocaine, amphetamine and MDMA, as well as 
mephedrone. In these cases, users may be unaware that they are consuming MDPV. 
Additional research is required in order to examine to what extent the characteristics 
of MDPV users reflect those who use other stimulant drugs. 
Route of administration, dose and drug regimens 
 
(21) See also Watterson et al., (2013).  
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Information provided by the Member States, as well as from case reports/series and 
user websites suggests the routes of administration for MDPV were mainly nasal 
(insufflation/sniffing) and oral (swallowing) or intravenous injection. Two countries 
reported that MDPV was detected in paper blotters and therefore buccal or 
sublingual administration may also occur. Furthermore, two countries reported the 
presence of MDPV in vegetable material, and this product would most probably be 
smoked. Information from user websites suggests that rectal administration may also 
be a route used. 
Information from case reports/series and user websites suggest a range of doses are 
used that may depend on the route of administration. The Erowid user website 
includes a range of tentative ‘common doses’ for three routes of administration: 
insufflation 5-11 mg; oral 8-15 mg; rectal 6-12 mg (Erowid, 2013a). One case report 
noted that MDPV produces psychoactive effects with as little as 3 to 5 mg, depending 
on its route of administration, and the average dose is approximately 5 to 20 mg. This 
report goes on to say that repeated dosing is common to avoid unpleasant come-
down being described with large single doses (Ross et al., 2012).  
France also reported cases identified on the basis of interviews with patients. For one 
of these cases, the patient reported suffering malaise, tetany, language disorders 
and respiratory distress after taking MDPV by injection. Another patient suffered 
abnormal movements, trismus, profuse sweating, visual disorders, insomnia, 
anorexia, dysuria, vertigo and dysuria for 24 hours after he had injected the drug. He 
also reported having taken 4-MEC. Another patient suffered agitation, confusion and 
had attempted suicide after injecting the drug. He also reported taking MDMA and 
‘cathinone’ as well. In addition, other symptoms reported included reduced appetite 
and weight loss, insomnia, loss of focus, absences, paranoia, sensation of cold and 
sensation of electrical discharge in heels by patients who had taken MDPV 
intransally. The drug had been bought on the internet. A range of other effects were 
also noted, such as insomnia, psychomotor agitation (experienced for three days by 
an injecting user); anxiety, intellectual stimulation, obsession to consume MDPV, 
withdrawal symptoms, fatigue, sleep disorder and pain at the site of injection; chest 
pain, accelerated heart rate and sensation of warmth (injecting user); agitation, facial 
erythrosis, dryness of the mucous and anxiety for 5 days for a patient with intranasal 
use. Two others reported sexual stimulation and increased sociability. 
Two studies are available that report the injection of MDPV, although its injection is 
documented in other countries, such as France, Romania and Finland. In the first 
study, 183 clients of a needle exchange programme in Hungary agreed to report their 
drug using habits (Csák et al., 2013). This study found that during 2011, changes 
occurred in the nature of primary injected substances: amphetamine was cited as the 
primary injected substance by 45.9% of the respondents and MDPV by 48.1%. 
Almost half of the former amphetamine injectors had switched to MDPV (64 persons, 
45.1%) as had 10 (41.7%) of the former heroin injectors and 11 (78.6%) of those 
using other substances (cocaine and mephedrone). The second study (Lindeman, et 
al., 2013), also mentioned in Section 3.4.1, was initiated due to a sharp rise in the 
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number of enquiries to the Swedish Poisons Information Centre regarding 
intoxications with MDPV. Of particular note is that of the patients with confirmed or 
suspected MDPV consumption, 95% were classified as chronic drug users and > 
60% were reported as positive for hepatitis virus C.  
Information from user websites suggest that MDPV may be used on its own as well 
as in combination with other new psychoactive substances, controlled drugs and/or 
prescription medication (Erowid, 2013b; Drugs Forum, 2013). In most of the cases of 
non-fatal intoxications and deaths reported by the Member States other new 
psychoactive substances and/or controlled drugs were detected in biological samples 
(Section 3.4.1 and Annex 2). 
Subjective effects 
No studies were identified that have examined the subjective effects of MDPV in 
humans; information is largely limited to that provided in case reports/series (see 
‘non-fatal intoxications’ and section above) and self-reported experiences from user 
websites. Table 2 provides an overview of self-reported duration of effects when 
MDPV is taken by the oral and insufflated routes as reported by Erowid (2013c). 
Table 3 provides an overview of subjective effects of MDPV as reported by Erowid 
(2013c). In both cases, the information was collated from users, research, and other 
resources. No further details were provided on the methodology used to collate this 
information. Information provided in case reports and case series of non-fatal 
intoxications associated with MDPV appear to support some of these effects. The 
section on ‘non-fatal intoxications’, above, provides an overview of the other adverse 
effects reported to be associated with MDPV. 
Table 2. Examples of self-reported duration of effects of MDPV per route of 
administration (tentative) as reported by Erowid (2013c). No information on the doses 
that were used was provided. 
Duration of effects for MDPV Oral Insufflated 
Total Duration 2.0–7.0 hrs 2.0–3.5 hrs 
Onset 15–30 mins 5–20 mins 
Coming Up 30–60 mins 15–30 mins 
Plateau 30–180 mins 30–100 mins 
Coming Down 30–120 mins 30–60 mins 
After effects 2–48 hours 1–7 days 
Hangover / Day After ? ? 
 
Table 3. Examples of subjective effects of MDPV as reported by Erowid (2013a). No 
information on the doses that were used was provided. 
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Subjective effects of MDPV 
Positive Stimulation (mental and physical) 
Euphoria, mood lift 
Increased sociability / talkativeness 
Increased productivity and motivation 
Increased mental clarity 
Enhanced creativity 
Feelings of empathy 
Sexual arousal 
Neutral Stimulation (mental and physical) 
Mild elevation in heart rate 
Negative (Likelihood of negative side effects increases with higher doses) 
Tightened jaw muscles, grinding teeth (trismus and bruxia) 
Reduced enjoyment of eating / loss of appetite 
Disturbed sleep patterns 
Involuntary body movements (twitching, lip-smacking, etc.) 
Confusion and/or scrambled thoughts 
Gastrointestinal disturbance 
Muscle tension 
Residual depressed mood 
Nystagmus / eye spasm 
Anxiousness / nervousness / paranoia 
Harsh comedown effects 
Fiending (redosing repeatedly without planning to do so) 
Excessive excitation / hyperactivity 
Headache 
Very elevated heart rate 
Hallucinations / psychotic behavior (at high doses or with repeated use) 
Availability, supply, price 
A search of google.com using the search string ‘buy ‘MDPV’’ conducted by the 
EMCDDA in December 2013 for the Joint Report identified a number of online shops 
offering MDPV for sale in both retail and wholesale quantities. In the former case, 
MDPV may be sold as a ‘research chemical’. 
Data from the National Drug and Alcohol Research Centre’s deep web monitoring 
programme of the Silk Road marketplace (22,23) (Van Buskirk et al., 2013) identified 
seven retailers in early February 2013 offering MDPV for sale. Details of the specific 
quantities and prices were not provided. The number of such retailers was relatively 
 
(22)  The National Drug and Alcohol Research Centre (NDARC) is based at the University of New 
South Wales, Sydney, Australia  
(23)  Silk Road is an anonymous, international online marketplace that operates as a Tor hidden 
service. It uses the peer-to-peer payment network and digital currency Bitcoin for monetary 
transactions. The original Silk Road marketplace was seized and taken offline on 2 October 
2013 by the United States Federal Bureau of Investigation. Since then a new version of Silk 
Road, sometimes described as ‘Silk Road 2.0’, has become operational. See Christin (2012) 
for an overview of the original Silk Road. 
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stable over the preceding four months of monitoring (24). It is important to note that 
the study was conducted before Silk Road was seized and taken offline in October 
2013 by the United States Federal Bureau of Investigation. No studies were identified 
that have examined the sale of MDPV since Silk Road has reopened. 
Seizure data as well as information from collected samples reported by the Member 
States suggests that MDPV is sold as a drug in its own right and directly on the illicit 
drug market as cocaine, amphetamine, MDMA and mephedrone. 
3.5 Information on whether or not the new substance is currently under 
assessment, or has been under assessment, by the UN system — 
Article 5.2(e) of the Decision 
The World Health Organization is the specialised United Nations agency designated 
for the evaluation of the medical, scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 1961 and the 
Convention on Psychotropic Substances, 1971. On 10 October 2013, the World 
Health Organization informed the EMCDDA that MDPV is currently under 
assessment and ‘the critical review report will be published only early next year 
(probably April)’.  
Article 7.1 of Council Decision states that ‘no risk assessment shall be carried out in 
the absence of a Europol/EMCDDA Joint Report. Nor shall a risk assessment be 
carried out where the new psychoactive substance concerned is at an advanced 
stage of assessment within the United Nations system, namely once the WHO expert 
committee on drug dependence has published its critical review together with a 
written recommendation, except where there is significant new information that is 
relevant in the framework of this Decision’.  
The Joint Report has been produced on the understanding that MDPV is not at an 
advanced stage of assessment within the United Nations system. 
3.6 The date of notification on the Reporting Form of the new psychoactive 
substance to the EMCDDA or to Europol — Article 5.2(f) of the Decision 
The first official EMCDDA–Europol notification of MDPV dates from December 2008 
from the Finnish National Focal Point. The Reporting Form details a seizure of two 
quantities of white powder (each of 1 gram) intercepted by customs authorities on 24 
November 2008 in incoming mail. The powders were in packages marked ‘1-(3,4-
 
(24)  Nine retailers were identified in late October 2012; 10 in mid-November 2012; 10 in late 
November 2012; 10 in mid-December 2012; 9 in early January 2013; and 9 in mid-January 
2013. See Christin (2012) for a discussion of some of the market characteristics and dynamics 
of the original Silk Road. 
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methylenedioxyphenyl)-2-pyrrolidinyl-pentan-1-one, purity 99 +%, 1g’. Identification 
was based on the analytical technique of GC-MS (25). 
MDPV was added to the list of new psychoactive substances monitored by the 
EMCDDA and Europol through the European Union early warning system and a 
profile of the substance was created in the EMCDDA European Database on New 
Drugs (EDND). Since then analytical details, background information and information  
relevant to public health have been exchanged between EMCDDA, Europol and the 
Member States on an ad hoc basis. The Commission and the EMA were kept duly 
informed. 
3.7 Information on whether or not the new psychoactive substance is 
already subject to control measures at national level in a Member State 
— Article 5.2(g) of the Decision 
Twenty Member States (Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, 
Denmark, Estonia, France, Germany, Hungary, Ireland, Finland, Italy, Latvia, 
Luxembourg, Poland, Slovakia, Slovenia, Sweden, and the United Kingdom) as well 
as Turkey and Norway control MDPV under drug control legislation.  
In Belgium it was added to the list of substances on 20 March 2013. In Bulgaria it is 
controlled under the Narcotic Substances Control Law since February 2011. In 
Croatia it is included in the List of drugs, psychotropic substances, plants used to 
produce drugs and substances that can be used in the production of drugs. In Cyprus 
it is controlled under the Narcotic Drugs and Psychotropic Substances Law of 1977 
as a class B drug that is covered by the generic definition of cathinones. In the Czech 
Republic it has been included in the Act 167/1998 Coll. on addictive substances. In 
Denmark it is covered by the Executive Order on Euphoriant Substances. In Estonia 
it is listed in the Regulation No.73 of the Minister of Social Affairs since 29 November 
2010. In Finland it has been listed in the Narcotics Act 373 of 2008 since 28 June 
2010. In France it was added to the controlled narcotic substance list since 2 August 
2012. In Germany it is included in the list covered by the Narcotic Substance Law 
since 26 July 2012. In Hungary it is listed in Schedule A (psychotropic substances) of 
Act XXV of 1998 on human pharmaceuticals. In Ireland it was covered by the Misuse 
of Drugs Acts since 11 May 2010. In Italy it is controlled generically as it is a 
derivative of 2-amino-1-phenyl-1-propanone, under the Decree of the President of 
the Republic 309/90 since 29 December 2011. In Latvia it is controlled according to 
Cabinet Regulation 847 ‘Regulations regarding narcotic substances, psychotropic 
substances and precursors to be controlled in Latvia’. In Luxembourg it has been 
controlled by the drug control legislation since 30 July 2012. In Poland it is covered 
by the Act of 15 April 2011 amending the Act of Counteracting Drug Addiction. In 
Slovakia it is in the 1st. schedule of psychotropic substances set by the Act. No 
139/1998 Coll. as amended by the Act. No 43/2011 Coll., which came into force on 1 
March 2011. In Slovenia it was included by the Decree on amending the Decree on 
 
(25)  Gas chromatography-mass spectrometry 
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classification of illicit drugs, Official Gazette of RS No. 62/2013. In Sweden it comes 
under the Narcotic drugs control Act (SFS 1992-860) and the Narcotic drugs control 
Ordinance (SFS 1994:1554). In the United Kingdom, it was included in the generic 
definition of substituted cathinone derivatives placed under the Misuse of Drugs Act 
1971 in April 2010. In Turkey it is listed in the Law on Control of Narcotics no.2313. In 
Norway it has been included by generic scheduling since 14 February 2013. 
Three Member States (Austria, Portugal and Romania) control MDPV under 
legislation penalising unauthorised supply of defined or qualifying new psychoactive 
substances. In Austria it is controlled under the generic definition within the New 
Psychoactive Substances Act. In Portugal it is listed as controlled under Decree-Law 
54/2013. In Romania the Law 194/2011 subjects to control any psychoactive 
substance that qualifies by conforming to certain criteria (all substances with 
psychoactive potential are subject to control until proven harmless by a special 
designated commission).  
In the Netherlands, the sale of MDPV in consumer amounts it is treated as being a 
medicinal product and must comply with medicines legislation (and general product 
safety legislation).  
Greece, Lithuania and Malta have reported that MDPV is not subject to control 
measures at the national level.  
No information was provided regarding the control status of MDPV in Spain. 
3.8 Further information — Article 5.2(h) of the Decision 
3.8.1 The chemical precursors that are known to have been used for the 
manufacture of the substance 
 
No information was reported by the Member States, Turkey or Norway about the 
chemical precursors or manufacturing methods used to make MDPV. Methods for 
the production of MDPV are documented in the scientific literature. 
3.8.2 The mode and scope of the established or expected use of the new 
substance 
 
MDPV has been marketed and sold through online shops as a branded ‘legal high’ 
product and as a ‘research chemical’. MDPV was not declared as an ingredient of the 
products. This has been confirmed by Denmark, Slovakia and the United Kingdom, 
each of which reported finding MDPV in samples of branded legal high products 
purchased from the Internet. Furthermore, both Ireland and Poland reported 
significant numbers of branded ‘legal high’ products collected from bricks and mortar 
shops (Kelleher et al.,2011). It is also important to note that information from the 
Member States (such as seizures, collected samples and non-fatal intoxications) and 
also from user websites suggest that MDPV may be commonly sold as a ‘legal’ 
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replacement for cocaine, amphetamine or MDMA. It is also sold directly on the illicit 
drug market as these drugs (26). The use of MDPV by injecting drug users has also 
been noted (see below). As a result, the mode and scope of use of MDPV may, in 
part, overlap and/or reflect the mode and scope of use of other stimulants used in 
recreational settings and by problematic drug users including those who inject. 
Additional research is required in order to examine to what extent, if any, the mode 
and scope of MDPV use overlaps and/or reflects those groups. 
Settings of use 
One of the deaths reported by Poland noted the use of MDPV in the context of 
recreational use (at a party). Samples have been collected from dance venues in 
Austria and the Netherlands where it was reported to have been sold as 
mephedrone, cocaine, MDPV and speed (Austria), and cocaine, synthetic cocaine, 
‘moji’, 6-APB, 5-APB, MDPV and ‘meferon’ (the Netherlands). France reported that 
MDPV was ‘generally used at home during sexual context’ (not further described). 
Sweden reported that ‘MDPV was popular two years ago among stimulant users, age 
group 20-30 years; they used MDPV at parties or at home (private parties that lasted 
from Friday night till Sunday night) and at times not regularly; at the moment MDPV 
is not present, the users stopped using it because of negative side effects, mostly 
depression and strong craving.’ 
Price 
Six countries reported the price of MDPV. France reported that MDPV was sold at 
between 2 and 15 EUR per gram. Hungary reported a price of 13.5 EUR (quantity not 
specified). Italy reported that prices were from 14.95 EUR for 0.5 grams to 169 EUR 
for 10 grams (source: http://www.spicestore247.biz/mdpv-1). The Netherlands 
reported information from a forum discussion which included prices for MDPV of 35 
EUR per gram and 160 EUR for 5 grams. Romania reported a price of 25 EUR 
(quantity not specified). Spain reported that when MDPV was sold as cocaine the 
price was 50 to 60 EUR per gram and when it was sold as MDPV the price was 20 
EUR per gram. In 2011, the EMCDDA conducted a study of Internet sites selling new 
psychoactive substances (EMCDDA, 2012). MDPV was found to be on sale in 
January 2011 and July 2011 in 25 and 32 shops respectively and the price was 
reported to be 115 to 239 EUR for 10 grams. 
3.8.3 Other use of the new psychoactive substance and the extent of such 
use, the risks associated with this use of the new psychoactive 
substance, including the health and social risks 
 
No information was provided by any Member State, Turkey or Norway that indicated 
that MDPV had any other use apart from legitimate scientific research and as an 
analytical reference standard. 
 
 
(26)  Other NPS and adulterants such as caffeine and lidocaine have been found in samples. 
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From the available information it does not appear that MDPV is used in the 
manufacture of a medicinal product in the European Union. However, the collection 
of information cannot be considered exhaustive in the absence of an European Union 
database on the synthetic routes of all medicinal products (27). 
4. Information from the EMA as requested by Article 5.3 of the Decision 
4.1 Marketing authorisation 
Twenty-five Member States, Norway and Iceland responded to the EMA’s information 
request (see section 2) reported that the new psychoactive substance MDPV has not 
obtained a marketing authorisation (28).The EMA also reported that the new 
psychoactive substance MDPV has not obtained a marketing authorisation through 
the central authorisation procedure. 
4.2 Application for a marketing authorisation 
Twenty-five Member States, Norway and Iceland responded to the EMA’s information 
request (see section 2) reported that the new psychoactive substance MDPV is not 
the subject of an application for a marketing authorisation (28). The EMA also 
reported that the new psychoactive substance MDPV is not the subject of an 
application for a marketing authorisation through the central authorisation procedure. 
4.3 Suspended marketing authorisation 
Twenty-five Member States, Norway and Iceland responded to the EMA’s information 
request (see section 2) reported that there had been no cases of a suspended 
marketing authorisation that had been granted in respect of the new psychoactive 
substance MDPV (28). The EMA also reported that the new psychoactive substance 
MDPV is not the subject of a suspended marketing authorisation through the central 
authorisation procedure. 
5. Conclusions 
MDPV is a synthetic cathinone derivative, which is closely related to pyrovalerone. 
MDPV has been present in the EU drug market since at least November 2008 and 
has been detected in up to 107 non-fatal intoxications and 99 deaths, particularly in 
 
(27) i.e. products that have been granted a marketing authorisation, or where an application for a 
marketing authorisation has been made, or where the marketing authorisation has been 
suspended. 
(28) Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, 
Iceland, Ireland, Netherlands, Norway, Portugal, Slovenia, Spain, Sweden and the United 
Kingdom provided responses in relation to both human and veterinary medicinal products. 
Cyprus, Italy, Lithuania, Malta, Romania and Slovakia provided responses in relation to human 
medicinal products. France, Latvia and Poland provided responses in relation to veterinary 
medicinal products. In addition the EMA provided information in relation to both human and 
veterinary medicinal products in respect to the central authorisation procedure. 
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Finland and the United Kingdom. There are some indications that it has been sold as 
a ‘legal’ or synthetic version of cocaine and it has also been found in tablets 
resembling ‘ecstasy’. Large seizures have been made at borders and police 
operations have targeted its supply. Powder seizures have been reported including 
multi-kilogram quantities. Most, but not all the Member States have control measures 
at national level that cover MDPV, however, it continues to be available and this is 
concerning. We conclude that the health and social risks caused by the manufacture, 
trafficking and use of MDPV, and in particular the involvement of organised crime 
and possible consequences of EU-level control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA. 
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Annex 1 
 
 
EMCDDA–Europol Joint Report 
on a new psychoactive substance: MDPV 
 
 
Images of MDPV from seizures and collected samples 
 
 
Country Image Description 
 
Belgium 
 
  
 
 
Seizure, November 2010 
40.35 g white powder divided over 74 small bags, 
seized in Brussels. 
Seizing authority: police 
 
 
Germany 
 
 
 
 
Seizure, September 2010 
1 kilo of a white powder, seized in Feucht. 
Seizing authority: police 
 
 
Hungary 
 
 
 
 
Seizure, July 2009 
300 yellow tablets, seized in Budapest. 
Seizing authority: police 
 
 
Hungary 
 
 
 
 
Seizure, April 2011 
2 white tablets, seized in Pest county. 
Contents: MDPV and 4-FMC. 
Seizing authority: police 
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Ireland 
 
 
 
 
 
Collected sample, analysed in March 2010 
white/off-white powder (Hurricane Charlie, Dogs 
Bollix, Doves Red, Doves Ultra, Ivory Wave, Sextasy, 
Orange Orbits, Stardust), head-shop 
 
 
Italy 
 
 
 
Seizures, 2011 
Numerous seized samples (powders, agglomerated 
powders, tablets), seized in Treviso. 
Contents: MDPV, 4-FA, cocaine and lidocaine or 
procaine. 
Seizing authority: Police Department, Treviso 
 
Malta 
 
 
 
Seizure, March 2011 
30 packets containing white powder – 15 g in all., 
seized in Attard. (€ 13.5 per gram) 
Seizing authority: Police Drug Squad 
 
 
Slovakia 
 
 
 
 
Collected sample, analysed in March 2010 
310 mg deep blue powder, colourless capsule  
Contents: MDPV and mephedrone not quantified 
Collecting authority: National Drug Service of Bureau 
of Fight against Organised Crime Police Force 
Headquarters; analyse was completed by Institute of 
the Forensic Science of Police Force (IFS).  
 
 
Slovakia 
 
 
Collected sample, analysed in September 2010 
310 mg white powder, colourless capsule  
Contents: MDPV and Butylone not quantified 
Collecting authority: National Drug Service of Bureau 
of Fight against Organised Crime Police Force 
Headquarters; analyse was completed by Institute of 
the Forensic Science of Police Force (IFS).  
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 Annex 2 — Table of non-fatal intoxications and deaths where MDPV has been analytically confirmed in biological samples 
Non-fatal intoxications 
Country Date Sample 
type 
MDPV result Results for other substances Notes 
Belgium Aug 2011 
(F, 31) 
Urine + cocaine (+) 
amphetamines (+) 
First time MDPV use. Drug taken orally. Symptoms included 
hallucinations and severe psychosis, paranoia, visual and auditory 
hallucinations, aggressiveness. Hypertension, tachycardia. Treated 
with antipsychotics. Status normal after 3-4 days 
Belgium Aug 2011 
(M, 34) 
Urine + cocaine (+) 
amphetamines (+) 
First time MDPV use. Drug taken orally. Symptoms included 
hallucinations and severe psychosis, paranoia, visual and auditory 
hallucinations, aggressiveness. Hypertension, tachycardia. Treated 
with antipsychotics. Status normal after 3-4 days 
This case is related to the case described above.  
France Date not 
specified 
(M, 27) 
Not 
specified 
+ pyrovalerone (+) 
cannabis (+) 
Symptoms included delirium syndrome, hallucination. 
Rhabdomyolysis, tachycardia, hypotension, agitation, logorrhea, 
acute renal failure. 
Man brought in to the emergency by the police. 
France Date not 
specified 
(M, 25) 
Blood + methylone (4400 ng/ml) Symptoms included tachycardia, mydriasis, hypertension, agitation, 
profuse sweating, trembling, scarification, rhabdomyolysis. Paranoid 
Psychosis, aggressivity. Route of administration: inhaled and oral. 
10g. Bought on the internet. In combination with methylone. 
Forced hospitalization 
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Country Date Sample 
type 
MDPV result Results for other substances Notes 
France Date not 
specified 
(M, 22) 
Hair + alcohol (+) 
cannabis (+) 
Intranasal ingestion. Duration of action: 2 days.  
Symptoms: mydriasis, paranoid psychosis.  
Italy Aug  2011 
(M, 20) 
Urine 14 mg/L butylone (+) 
 
On admission, the patient was very agitated with tachycardia (Fc 
115 bpm). He reported having consumed cannabis, alcohol and 3 
white capsules. He was treated with benzodiazepine and 
discharged two days later. 
Italy Oct 2012 
(M, 38) 
Blood 
Urine 
12 mg/L 
   (blood) 
17 mg/L 
   (urine) 
Urine: 
  ketamine (-) 
  atropine (-) 
  scopolamine (-) 
  levamisole (-) 
  mephedrone (-) 
  butylone (-) 
  4-methylethcathinone (-) 
  methoxetamine (-) 
  APB (29) isomers (-) 
  4-fluoroamphetamine (-) 
  MDAI (30) (-) 
The patient was admitted to the emergency department and 
reported having consumed (sniffing) ecstasy and synthetic drugs 
generally named as “mefre, crystal and energy”. 
Symptoms included agitation, mild tachycardia (Fc 105 bpm), 
distress, psychotic symptoms, visual and auditory hallucinations. 
During the first 24 hours, the patient was treated with fluids, 
benzodiazepine and haloperidol and transferred to a psychiatric 
ward. 
 
29
 (Aminopropyl)benzofuran 
30
 3,4-Methylenedioxyaminoindane 
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Country Date Sample 
type 
MDPV result Results for other substances Notes 
Italy Oct 2012 
(M, 27) 
Urine On 
admission: 
   55 µg/L 
Three days 
after 
admission: 
   35 µg/L 
On admission:  
  alprazolam (113.79 µg/L) 
  hydroxyalprazolam (103.59 µg/L) 
3 days after admission: 
  chlordiazepoxide (13.03 µg/L) 
  nordiazepam (61.55 µg/L) 
  oxazepam (114.99 µg/L) 
  diazepam (1.26 µg/L) 
  temazepam (169.90 µg/L) 
  alprazolam (10.43 µg/L) 
  alpha-hydroxyalprazolam (13.45 
µg/L) 
At arrival in the emergency department the patient reported having 
consumed 3,4-methylenedioxypyrovalerone (MDPV) intravenously, 
for the last 3-4 days together with benzodiazepine, to counteract the 
excitatory effect of MDPV. Symptoms included psychomotor 
agitation, confusion and anxiety. Anamnestic information from the 
patient revealed previous use of pentedrone and 3-
methylmethcathinone abandoned for decreased interest on these 
substances.  
Three days after admission, the patient had a second urine 
analyses, and reported having continued his use of MDPV 
MDPV was purchased via Internet and marketed as "bath salt" 
Sweden Jan – Sep  
2012 
Blood 
Urine 
+ Result for other substances was 
positive for 15/17 cases with 
severe symptoms. 
Benzodiazepines (7) were the most 
frequently identified substances. 
Medicines included buprenorphine, 
tramadol and fentanyl. 
From a total of 86 cases, in 17 cases the symptoms were severe 
(Poisoning Severity Score - PSS 3) and consisted of extreme 
agitation, psychosis, hyperthermia, tachycardia, hypertension, 
myocardial infarction, rhabdomyolysis and renal failure. A few 
patients needed therapy with sedatives for several days due to 
prolonged symptoms  
[Bäckberg et al., 2013] 
Sweden Apr-May 
2012 
Not 
specified 
+ None reported Twelve of the 13 cases described were classified as chronic drug 
users with >60% noted to be HCV-positive   
[Lindeman et al., 2013] 
 
41 
 
Deaths 
 
 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
1 Austria Jan 2012 
(M) 
Not specified + butylone (+) 
methylone (+) 
4-methylethcathinone (+) 
cocaine (+) 
Butylone (bk-MBDB) overdose in combination  
with methylone, 4-methylethcathinone and cocaine 
2 Finland* Sept 
2009 
Urine 
 
Blood 
+ (urine) Blood:  
  olanzapine (0.7 mg/L) 
  methadone (0.4 mg/L)  
  chlorprothixen (0.1 mg/L)  
  diazepam (0.03 mg/L)  
  amphetamine (8.4 mg/L) 
Accidental death, poisoning by narcotics  
3 Finland Sept 
2009 
Blood 40 mg/mL ethanol (1.5 g/kg)  
buprenorphine (0.001 mg/L)  
Accidental death, poisoning by narcotics 
4 Finland Oct 2009 Blood + diazepam (0.1 mg/L) 
temazepam (0.3 mg/L) 
morphine (0.6 mg/L) 
amphetamine (0.88 mg/L) 
THC (31) (<LOQ) 
Accidental death, poisoning by drugs or medicaments 
5 Finland Oct 2009 Urine 
 
Blood 
+ (urine) Blood:  
 alprazolam (0.1 mg/L) 
 tramadol (1.4 mg/L) 
 methadone (0.2 mg/L) 
 diazepam (0.02 mg/L) 
Accidental death, poisoning by drugs or medicaments  
 
31
 ∆9-tetrahydrocannabinol, the main psychoactive substance in cannabis 
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
6 Finland Oct 2009 Blood 840 mg/mL 
(estimated 
value) 
levomepromazine (2.4 mg/L) 
trimipramine (0.3 mg/L) 
oxycodone (2.2 mg/L) 
Suicide, poisoning by drugs or medicaments 
7 Finland Oct 2009 Urine 
 
Blood 
+ (urine) Blood:  
 zolpidem (0.4 mg/L) 
 citalopram (0.9 mg/L) 
 oxazepam (1.7 mg/L) 
 olanzapine (0.2 mg/L) 
 propranolol (2.1 mg/L) 
Suicide, propranolol poisoning  
8 Finland Feb 2010 Blood 4800 mg/mL Blood:  
 morphine (0.08 mg/L) 
 amphetamine (1.6 mg/L) 
Homicide, multiple injuries of neck 
9 Finland Feb 2010 Urine + temazepam (0.9 mg/L) 
diazepam (0.4 mg/L) 
amphetamine (7.3 mg/L) 
Suicide Hanging  
10 Finland Feb 2010 Blood 1800 mg/mL methadone (1.3 mg/L) 
temazepam (0.3 mg/L) 
diazepam (0.1 mg/L) 
amphetamine (0.06 mg/L) 
buprenorphine (0.0044 mg/L) 
Accidental death, poisoning by drugs or medicaments 
11 Finland Feb 2010 Urine 
 
Blood 
+ (urine) Blood:  
 tramadol (5.3 mg/L) 
 valproate (19 mg/L) 
 THC (32) (0.0061 mg/L) 
Accidental death, poisoning by drugs or medicaments  
 
32
 ∆9-tetrahydrocannabinol, the main psychoactive substance in cannabis 
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
12 Finland Feb 2010 Blood 70 mg/mL ethanol (0.22 g/kg) 
amphetamine (0.16 mg/L) 
Accidental death, Injury of thoracic aorta 
13 Finland Feb 2010 Blood + metoclopramide (0.3 mg/L) 
diazepam (0.1 mg/L) 
oxycodone (0.13 mg/L) 
Accidental death, poisoning by drugs or medicaments 
14 Finland Feb 2010 Blood + None reported Disease, infective myocarditis 
15 Finland Mar 2010 Blood 1200 mg/mL ethanol (1.3 g/kg) 
venlafaxine (8.7 mg/L) 
levomepromazine (0.4 mg/L) 
mirtazapine (0.3 mg/L) 
nordiazepam (0.05 mg/L) 
codeine (0.53 mg/L) 
buprenorphine )0.0032 mg/L) 
Accidental death, poisoning by drugs or medicaments 
16 Finland Mar 2010 Blood + ethanol (0.36 g/kg) 
venlafaxine (0.9 mg/L) 
alprazolam (0.05 mg/L) 
diazepam (0.34 mg/L) 
buprenorphine (0.0076 mg/L) 
Accidental death, poisoning by drugs or medicaments 
17 Finland Apr 2010 Blood 60 mg/mL oxazepam (0.46 mg/L) 
temazepam (0.096 mg/L) 
nordiazepam (0.024 mg/L) 
amphetamine (0.11 mg/L) 
buprenorphine (0.70 mg/L) 
Accidental death, poisoning by drugs or medicaments 
18 Finland Jun 2010 Liver 
 
Muscle 
+ (liver) Muscle: 
  ethanol (0.51 g/kg) 
Suicide, hanging  
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
19 Finland Jun 2010 Blood 40 mg/mL nordiazapam (0.12 mg/L) 
morphine (0.15 mg/L) 
codeine (0.02 mg/L) 
amphetamine (0.20 mg/L) 
oxycodone (<LOQ) 
THC (33) (+) 
Accidental death, poisoning by narcotics 
20 Finland Sep 2010 Blood 20 mg/mL methadone (0.3 mg/L) 
temazepam (0.13 mg/L) 
oxazepam (0.15 mg/L) 
nordiazepam (0.026 mg/L) 
amphetamine (+) 
Accidental death, poisoning by narcotics 
21 Finland Oct 2010 Blood 530 mg/mL diazepam (0.033 mg/L) 
DPMP (34) (+) 
methylone (+) 
Accidental death, poisoning by narcotics 
22 Finland Feb 2011 Hair 
 
Blood 
+ (hair) Blood :  
  amitriptyline (4.3 mg/L) 
  hydroxyzine (1.1 mg/L) 
  citalopram (0.7 mg/L) 
  perfenazine (0.21 mg/L) 
Suicide, poisoning by drugs or medicaments  
23 Finland Feb 2011 Urine 
 
Blood 
+ (urine) Blood:  
  alprazolam (0.018 mg/L) 
  methadone (0.4 mg/L) 
  diazepam (0.13 mg/L) 
Disease, other and unspecified cirrhosis of liver  
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 ∆9-tetrahydrocannabinol, the main psychoactive substance in cannabis 
34
 (Diphenylmethyl)piperidine. 
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
24 Finland Apr 2011 Blood + alprazolam (0.44 mg/L ) 
clonaxepam (0.12 mg/L) 
amphetamine (0.42 mg/L) 
buprenorphine (0.00042 mg/L) 
Suicide, crushing injury of skull 
25 Finland May 
2011 
Hair 
 
Blood 
+ (hair) Coronary blood:  
  temazepam (1.1 mg/L) 
  quetiapine (0.3 mg/L) 
  methadone (0.2 mg/L) 
  diazepam (0.029 mg/L) 
Accidental death, poisoning by drugs 
26 Finland May 
2011 
Hair 
 
Liver 
+ (hair) Liver: 
  temazepam (+) 
  methadone (+) 
  quetiapine (+) 
Accidental death, poisoning by drugs 
 
This case has a connection to case 25. The two deceased 
were found together 
27 Finland May 
2011 
Blood 110 mg/mL nordiazepam (0.20 mg/L) Suicide, toxic effect of carbon monoxide (COHb (35) 71% ) 
28 Finland Jun 2011 Urine + diazepam (0.30 mg/L) 
buprenorphine (0.0037 mg/L) 
alprazolam (+) 
clonazepam (+) 
Suicide, crushing injuries involving other combinations of 
body regions  
29 Finland Jul 2011 Blood 30 mg/mL methadone (0.6 mg/L) 
temazepam 0.22 mg/L) 
diazepam (0.15 mg/L) 
buprenorphine (0.0017 mg/L) 
Accidental death, poisoning by drugs or medicaments 
30 Finland Oct 2011 Blood 170 mg/mL 2,3-DMMC (36) (0.01 mg/L) 
amphetamine (1.8 mg/L) 
Accidental death, poisoning by narcotics 
 
35
 Carboxyhaemoglobin 
46 
 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
31 Finland Oct 2011 Blood 190 mg/mL methadone (1.1 mg/L) 
mirtazapine (0.07 mg/L) 
oxazepam (0.077 mg/L) 
amphetamine (0.24 mg/L) 
pregabalin (3.7 mg/L) 
Accidental death, poisoning by drugs or medicaments 
32 Finland Jan 2012 Hair + buprenorphine (+) 
verapamil (+) 
propofol (+) 
diazepam (+) 
Accidental death, poisoning by narcotics  
33 Finland Apr 2012 Blood 130 mg/mL fentanyl (0.0097 mg/L) 
clonazepam (0.005 mg/L) 
Accidental death, poisoning by narcotics 
34 Finland Jul 2012 Blood 1700 mg/mL olanzapine (0.3 mg/L) 
alprazolam (0.005 mg/L) 
GHB (37) (1500 mg/L) 
Accidental death, poisoning by narcotics 
35 Finland Jul 2012 Blood 80 mg/mL ethanol (0.23 g/kg) 
isopropylalcohol (0.1 g/kg) 
diazepam (0.048 mg/L) 
buprenorphine (0.0079 mg/L) 
Accidental death, poisoning by narcotics 
36 Finland Jul 2012 Blood 
 
Vitreous humor 
590 mg/mL 
(blood) 
Blood: 
  α-PVP (38) (0.60 mg/L) 
  amphetamine (1.6 mg/L)  
 
Vitreous humor:  
  ketamine (+) 
Accidental death, multiple fractures of ribs 
                                                                                                                                                                                                                                 
36
 2,3-dimethylmethcathinone 
37
 Gammahydroxybutyrate 
38
 α-Pyrrolidinovalerophenone 
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
37 Finland Nov 2012 Urine 
 
Blood 
+ (urine) Blood:  
  diazepam (0.064 mg/L) 
  buprenorphine (0.00066 mg/L) 
  pregabalin (4.4 mg/L)  
  amphetamine (< LOQ)  
Disease, intoxication -psychoactive substances  
38 Finland Dec 2012 Blood 30 mg/mL doxepine (1.5 mg/L) 
citalopram (1.9 mg/L) 
quetiapine (1.3 mg/L) 
α-PVP (0.070 mg/L) 
buprenorphine (0.029 mg/L) 
temazepam (<LOQ)  
Suicide, doxepin poisoning 
39 Finland Jan 2013 Urine + ethanol (1.6 g/kg) 
alprazolam (0.005 g/L) 
diazepam (0.45 g/L) 
codeine (0.15 g/L) 
buprenorphine )0.0006 g/L) 
Cause of death not yet registered  
40 Finland Apr 2013 Blood 30 mg/mL trimethoprim (1.6 mg/L)  Cause of death not yet registered 
41 Finland Aug 2013 Urine + alprazolam (0.044 mg/L) 
diazepam (0.092 mg/L) 
THC 39(0.0051 mg/L)  
buprenorphine (0.0012 mg/L) 
fentanyl (0.0082 mg/L) 
pregabalin (4.0 mg/L) 
Cause of death not yet registered 
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 ∆9-tetrahydrocannabinol, the main psychoactive substance in cannabis 
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
42 France Oct 2012 Blood 
 
Urine 
106 µg/L 
(blood) 
760 µg/L 
(urine) 
PVP  
  (40 µg/L in blood)  
  (295 µg/L in urine) 
pentedrone  
  (33 µg/L in blood) 
  (110 µg/L in urine)  
hydroxyzine (194 µg/L in blood) 
nordazepam (47 µg/L in blood) 
oxazepam (8 µg/L in blood) 
cannabinoic acid  
  (15.7 µg/L in blood) 
ethanol (0.3 g/L in blood) 
Cause of death was drowning  
43 Norway 2012 Blood + None reported Cause of death not reported. 
44 Poland Sep 2010 Blood 430 ng/mL ephedrine (324 ng/mL) Cause of death: ‘metabolic dysfunction’ caused by MDPV 
45 Poland 2011 Blood 38 ng/mL buphedrone (127 ng/mL) Indirect death: car accident. During inspection of the 
deceased driver, the police revealed packages of white 
powders, with the names Ivory Speed and Exclusive Dust 
and a note ‘collector’s product for field stone rinsing’ 
[Adamowicz et al., 2013] 
46 Poland 2011 Blood 17 ng/mL clonazepam (1.2 ng/mL) 
7-aminoclonazepam (96 ng/mL) 
Death after a night of partying, a witness testified that the 
man had taken a product called Speedway.  
 
The autopsy showed emaciation, external hydrocephalus 
and atherosclerosis. Deceased with a history of drug 
addiction, HIV+ [Adamowicz et. all 2013] 
47-
49 
Sweden 2010 Not specified + None reported 3 cases 
The deaths were intoxications involving several substances 
(not further described)  
49 
 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
50-
52 
Sweden 2011 Not specified + None reported 3 cases 
None of the 3 deaths related only to MDPV 
53-
61 
Sweden 2012 Not specified + None reported 9 cases 
There were several accidents, death by hanging and 
intoxications with several drugs (not further described) 
62-
67 
Sweden 2013 Not specified + None reported 6 cases 
There was one car accident and intoxications with several 
drugs (not further described) 
68-
69 
United 
Kingdom 
 
 
Jan-Dec 
2010 
Blood 
 
Urine 
 
 
+ Case 1 
  fluoromethcathinone (+) 
  mirtazapine(+) 
  olanzapine (+) 
  amphetamine (+) 
 
Case 2 
  fluoromethcathinone (+) 
  ibuprofen(+) 
2 cases 
 Case 1 – hit by train 
 Case 2 – bag over head  
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
70-
72 
United 
Kingdom 
 
 
Jan-Dec 
2011 
Blood 
 
Urine 
 
+ Case 1 
  ketamine (+) 
  
Case 2  
  quetiapine (+) 
  
Case 3 
  fluoromethcathinone (+) 
  MDMA (40) (+) 
  methylone (+) 
  MDAI (41) (+) 
  5-IAI (42) (+) 
  methoxetamine (+) 
  AMT (43) (+) 
3 cases 
 Case 1 – hanging  
 Case 2 – no circumstances reported 
 Case 3 – found at home 
73-
83 
United 
Kingdom 
** 
 
 
Jan-Dec 
2012 
Blood 
 
Urine 
 
+ None reported 11 cases 
 6 cases of hanging 
 1 case murder victim 
 1 case murder suspect 
 2 cases found dead at home 
 1 case found in a canal 
 1 case found dead in a car (carbon monoxide 
poisoning) 
 
(One of the cases is a duplicate, although it is not certain 
which one, hence this group is counted as 11 cases – see 
death 99) 
 
40
 Methylenedioxymethylamphetamine (commonly known as ‘ecstasy’) 
41
 3,4-Methylenedioxyaminoindane 
42
 5-Iodoaminoindane 
43
 Alpha-methyltryptamine 
51 
 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
84 United 
Kingdom 
 
 
Jan-Dec 
2013 
Blood 
 
Urine 
 
+ methadone (+) 
morphine (+)  
mirtazapine (+) 
diazepam (+) 
zopiclone (+) 
codeine (+) 
Methadone intoxication 
85 United 
Kingdom 
Jan 2010 
(M, 57) 
Blood 0.01 mg/L N-desalkyl-4-
methylmethcathinone (+) 
Coronary artery disease in the presence of MDPV. 
 
Coroner’s verdict: open verdict/unascertained.  
86 United 
Kingdom 
Feb 2010 
(M, 34) 
Blood 
 
Gastric 
+ (blood) fentanyl  
  (24 ng/mL in blood) 
  (37 µg in gastric sample) 
cannabis (+) 
Fentanyl toxicity implicated.  
 
Coroner’s verdict: open verdict/unascertained.  
87 United 
Kingdom 
Jul 2010 
(M, 26) 
Blood 
 
Gastric 
+ (blood) 
+ (gastric) 
pyrovalerone  
  (+ in blood)  
  (+ in gastric sample) 
THC-acid (44) (+ in blood) 
lignocaine  
  (+ in antemortem blood) 
amiodarone  
  (+ blood, therapeutic use 
suspected) 
Cause of hypovolaemic shock, laceration of left forearm 
associated with partial transection of cephalic vein. 
 
Toxic effects of pyrovalerone and MDPV. Coroner's verdict 
accidental / misadventure. 
88 United 
Kingdom 
 
Apr 2010 
(F, 45) 
Blood + mephedrone (+) 
GBL (45) (+) 
methylone (+) 
Mixed drug toxicity. Implicated: methedrone, GBL and 
methylone. Cause of death non-dependent abuse of drugs.  
 
Coroner’s verdict: open verdict/unascertained. 
 
44
 ∆9-tetrahydrocannabinolic acid, a breakdown product of ∆9-tetrahydrocannabinol, the main psychoactive substance in cannabis 
45
 Gammabutyrolactone 
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 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
89 United 
Kingdom 
** 
Nov 2010 
(F, 29) 
Blood 
 
Urine 
<LOD (blood) 
 
+ (urine) 
alcohol  
  (63 mg/100mL in blood) 
  (118 mg/100mL in urine) 
mephedrone   
  (<LOD (46) in matrix unknown) 
cocaine (+ in urine) 
levamisole (+ in urine) 
quinine (+ in urine) 
Multiple injuries. Had taken a variety of substances and 
alcohol.  
 
Coroner's verdict: suicide. Implicated drugs alcohol, 
mephedrone and MDPV 
90 United 
Kingdom 
Jun 2010 
(M, 39) 
Blood 0.13 µg/L 
 
alcohol (175 mg/100mL) 
citalopram (0.12 mg/L) 
diazepam (85 µg/L) 
temazepam (99 µg/L) 
 
Carbon monoxide poisoning, alcoholic liver disease. 
Implicated- 4-fluoromethcathinone and mephedrone 
 
Coroner's verdict: suicide.  
91 United 
Kingdom 
Apr 2010 
(M, 29) 
Blood 
 
Urine 
0.11 mg/L 
 
4-fluoromethcathinone  
  (0.21 mg/L in blood) 
  (23.62 mg/mL in urine  
mephedrone  
  (<0.05 mg/L  in urine)  
ibuprofen (+ blood) 
Asphyxia. Implicated: 4-fluoromethcathinone and 
mephedrone.  
 
Coroner's verdict: accidental/misadventure. 
92 United 
Kingdom 
Jun 2010 
(M, 38) 
Blood 
 
Urine 
 
0.41 mg/L 
(blood) 
0.75 mg/L 
(urine) 
amphetamine (+ blood) 
mephedrone   
  (0.05 mg/L in blood) 
  (0.05 mg/L in urine) 
4-fluoromethcathinone  
  (0.55 mg/L in blood)  
  (6.51 mg/L in urine) 
 
Cardiac arrest caused by either multiple drug toxicity or 
excited delirium 
 
Coroner's verdict: accidental/misadventure 
 
46
 Limit of detection – the lowest amount that can be detected by the method used. 
53 
 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
93 United 
Kingdom 
Jun 2010 
(M, 33) 
Unspecified 1.5 mg/L alcohol (57 mg/100 mL) 
benzodiazepine (7.4 mg/L) 
TFMPP (47) (1.9 mg/L) 
lignocaine (+) 
Cause of death unascertained.   
 
Coroner's verdict: open verdict/unascertained. 
94 United 
Kingdom 
Feb 2011 
(M, 37) 
Blood 
 
Nasal swab 
+ (blood) 
+ (nasal swab) 
both low level 
amphetamine  
  (0.04 µg/mL in blood) 
  (+ on nasal swab) 
lignocaine (+ on nasal swab) 
benzocaine (+ on nasal swab) 
sertraline (+ in blood) 
diazepam (+ in blood) 
Hanging.  
 
Coroner's verdict: open verdict/unascertained.  
95 United 
Kingdom 
Apr 2011 
(M, 24) 
Blood 1.63 mg/L MDMA (48) (7460 µg/L) 
cocaine (929 µg/L) 
benzoylecgonine (1.89 mg/L) 
mephedrone (0.17 mg/mL) 
diazepam (3284 µg/L) 
nordiazepam (1138 µg/L) 
Drowning and multiple drug overdose. Implicated- MDMA, 
cocaine and mephedrone 
 
Coroner's verdict: accidental/misadventure 
96 United 
Kingdom 
** 
May 
2011 
(M, 53) 
Blood 
 
Urine 
+ MDPBP (49) 
  (1.55 mg/l in blood),  
  (94.2 mg/l in urine) 
pentylone  
  (0.34 mg/l in blood)  
  (29.4 mg/l in urine) 
mephedrone  
  (+ in matrix unknown) 
cocaine (+ in urine) 
Cause of death: ischemic heart disease and illicit use of 
cathinones.  Implicated drugs: mephedrone, MDPBP and 
pentylone  
 
Coroner's verdict accidental/misadventure 
 
 
47
 Trifluoromethylphenylpiperazine 
48
 Methylenedioxymethylamphetamine (commonly known as ‘ecstasy’) 
54 
 Country Date Biological 
sample 
MDPV result Results of toxicological 
analysis for other substances 
Notes 
97 United 
Kingdom 
 
Dec 2011 
(M, 56) 
Not specified + MDMA (21) (+) 
cocaine (+) 
cathinone (+) 
MDMA, cocaine, MDPV and methylmethcathinone toxicity. 
Implicated: ecstasy, cocaine and cathinones 
 
Coroner’s verdict: open verdict/unascertained 
98 United 
Kingdom 
Aug 2011 
(M, 27) 
Unspecified + None reported MDPV and heart attack.  
 
Coroner's verdict: open verdict/unascertaine 
99 United 
Kingdom 
** 
 
Apr 2012 
(M, 31) 
Blood <0.1 mg/L AMT (50) (0.89 mg/L) Cause of death cardiac failure, MDPV and AMT drug toxicity 
plus left ventricular hypertrophy and obesity. 
 
Coroners’ verdict: accidental/misadventure 
 
In this table LOD is the limit of detection and LOQ is the limit of quantitation. 
 
* All cases in Finland are from medico-legal source and include suspect and unnatural deaths, non-related to poisoning.  
** The United Kingdom reported data on fatal intoxications from two separate sources, ROAR Forensics and the national programme for 
Substance Abuse Deaths (np-SAD). It should be noted that based on case specific details, case 99 is believed to be a duplicate of one of the 
cases reported in the aggregated data from 2012 and has been counted once only. 
 
 
                                                                                                                                                                                                                                 
49
 3,4-Methylenedioxy-α-pyrrolidinobutyrophenone 
50
 Alpha-methyltryptamine 
